Drugs / TQC3564
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05607446 | Sep 2022 → May 2023 | allergic rhinitis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQC3564 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05607446 ↗ |
| Action | Inhibit | “TQC3564 tablets are CRTH2 antagonists.” NCT05607446 ↗ |
| Route | Oral | “Orally administer TQC3564 tablets for 14 days.” NCT05607446 ↗ |